Navigation Links
The Trendlines Group Announces Co-development Agreement with Endo
Date:11/13/2012

TEL AVIV, Israel, November 13, 2012 /PRNewswire/ --

The Trendlines Group today announced it has entered into an R&D agreement aimed at co-developing novel medical devices and technologies within the areas of pain and urology, a strategic focus  of U.S.-based Endo Health Solutions Inc. (Nasdaq: ENDP).  

The work will be conducted by Trendlines Labs, the technology development arm of The Trendlines Group.  Trendlines Labs is co-located with the Misgav Venture Accelerator - The Trendlines Group's incubator focused exclusively on the development of medtech innovations.  Misgav was named "Best Incubator" by Israel's Office of the Chief Scientist of the Ministry of Industry, Trade and Labor in 2010. Trendlines portfolio company Stimatix (http://www.stimatix-gi.com) was named Israel's best start-up in 2012.

D. Todd Dollinger, Chairman and CEO of Trendlines, stated, "Our work with Endo furthers our market reach and is instrumental to our achieving our mission of creating and developing businesses to improve the human condition."  

Dr. Sujat Sukthankar, Vice President, Device R&D, at Endo said, "The Trendlines-Endo agreement is in line with our stated vision of sourcing innovation globally.  This partnership complements and bolsters our own internal innovation and product development efforts in the areas of pain and urology.  Through this partnership, we are excited to participate in the vibrant medical technology community in Israel. "  

Endo Health Solutions Inc. (http://www.endo.com) is a U.S.-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through its operating companies: Endo Pharmaceuticals, Qualitest, AMS and HealthTronics, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike.

About The Trendlines Group

The Trendlines Group (http://www.trendlines.com) creates and develops businesses to improve the human condition.  Principally through its two Israeli government-licensed business accelerators, Trendlines invests in innovation-based businesses in the areas of medtech and agritech, nurturing high-promise companies while mitigating seed-stage investment risk. The Trendlines group owns the Misgav Venture Accelerator (http://www.misgav-venture.com) which invests in and incubates promising medical device companies and Trendlines Labs, which acts as Trendlines' in-house invention factory, inventing solutions to unmet market needs.

Media relations:
Efrat Sherer-Kaduri
Ofir Shpigel Media and Public Relations
+972-4-9535030


'/>"/>
SOURCE The Trendlines Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
2. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
3. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
4. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
5. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
6. VWR International, LLC Acquires Sovereign Group
7. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
8. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
9. Astrix Technology Group Awarded Department of Homeland Security BioWatch Laboratory Staffing Contract
10. EAS Consulting Group Realigns Its Management for Growth
11. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Dutch philosopher Koert van Mensvoort - founder of the Next ... in Eindhoven - has written a ,Letter to Humanity, in support ... avoid becoming a slave and victim to its own technology, but to employ ... ... van Mensvoort – founder of the Next Nature Network and Fellow of ‘Next ...
(Date:4/20/2017)... 20, 2017 For today, Stock-Callers.com redirects ... drug development and clinical research aimed at treating diseases and ... BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: ... You can access our complimentary research reports on these stocks ... http://stock-callers.com/registration ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have ... is part of the Protein and Cell Analysis Education Webinar Series , will ... technology fits in current and future applications. , Many flow cytometers have unique ...
(Date:4/19/2017)... , ... April 18, 2017 , ... ... Halo Labs . The move comes after the company changed focus to making ... our new brand and our new technology,” says CEO Robert Hart. Founders Bernardo ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):